Adalimumab BS Subcutaneous Injection 40mg Pen 0.4mL "MA" (アダリムマブBS皮下注40mgペン0.4mL「MA」)

Valsts: Japāna

Valoda: angļu

Klimata pārmaiņas: すりの適正使用協議会 RAD-AR Council, Japan

Aktīvā sastāvdaļa:

Adalimumab(genetical recombination)[adalimumab biosimilar 3]

Pieejams no:

AYUMI Pharmaceutical Co., Ltd.

SNN (starptautisko nepatentēto nosaukumu):

Adalimumab(genetical recombination)[adalimumab biosimilar 3]

Zāļu forma:

colorless and almost limpid or slightly opalescent peculiar to protein injectable solution in a prefilled syringe with an injection needle contained inside a pen device for a single use

Lietošanas instrukcija

Drug Information Sheet("Kusuri-no-Shiori")
Self-injection
Revised: 07/2022
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
ADALIMUMAB BS SUBCUTANEOUS INJECTION
40MG PEN 0.4ML "MA"
ACTIVE INGREDIENT:
Adalimumab(genetical recombination)[adalimumab
biosimilar 3]
DOSAGE FORM:
colorless and almost limpid or slightly opalescent peculiar to
protein injectable solution in a prefilled syringe with an
injection needle contained inside a pen device for a single
use
IMPRINT OR PRINT ON WRAPPING:
EFFECTS OF THIS MEDICINE
This medicine suppresses the function of TNF (tumor necrosis
factor)-α, which is one of the
possible primary causative substances in rheumatoid arthritis,
psoriasis, ankylosing
spondylitis, juvenile idiopathic arthritis, intestinal Behcet's
disease, Crohn's disease and
ulcerative colitis. TNF is one of the cytokines existing inside of the
body even in a healthy
state, and involved in activities of immunity and development of
inflammation or pain.
It is usually used to treat rheumatoid arthritis (including prevention
of structural joint damage)
and the diseases described below with inadequate response to
conventional therapies:
psoriasis vulgaris, psoriasis arthritis or pustular psoriasis;
ankylosing spondylitis; active
polyarticular-juvenile idiopathic arthritis; intestinal Behcet's
disease; non-infectious
intermediate/posterior uveitis or panuveitis; and moderate to severe
ulcerative colitis. It is
also used for inducing clinical remission and maintenance therapy in
patient with moderately
to severely active Crohn's disease.
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you hav